Research programme: TransKingdom RNA interference therapeutics - Marina Biotech

Drug Profile

Research programme: TransKingdom RNA interference therapeutics - Marina Biotech

Alternative Names: tkRNAi therapeutic targeting beta-catenin (CTNNB1) - Marina Biotech; CEQ 400; CEQ 600; CEQ 700; CEQ-501; CEQ-626; tk RNAi; TransKingdom RNA interference

Latest Information Update: 06 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cequent Pharmaceuticals
  • Developer Marina Biotech
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Inflammatory bowel diseases
  • No development reported Human papillomavirus infections

Most Recent Events

  • 05 Aug 2015 Marina Biotech receives patent allowance for its transKingdom RNAi (tkRNAi) technology in USA
  • 23 Apr 2015 Marina Biotech receives patent allowance for transKingdom RNAi (tkRNAi) technology in USA
  • 25 Feb 2015 Marina Biotech has patent protection for transkingdom RNA interference therapeutics in Japan, Europe and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top